Calcitonin

Calcitonin is a 32-amino-acid peptide hormone produced by the parafollicular C cells of the thyroid gland. Synthetic salmon calcitonin (salcatonin) is approximately 40-fold more potent than human calcitonin at the receptor level and is the form used in all approved pharmaceutical preparations.

The primary skeletal target is the calcitonin receptor (CTR), a class B G protein-coupled receptor expressed at high density on osteoclasts and also present on renal tubular cells and neurons. CTR activation drives two intracellular cascades: adenylate cyclase raises cyclic AMP and activates protein kinase A to arrest osteoclast motility; and phospholipase C elevates intracellular calcium, disrupting the actin ring cytoskeletal structure that seals the resorption lacuna. Within minutes of exposure, osteoclasts retract their ruffled border — the specialized membrane responsible for secreting hydrochloric acid and lysosomal proteases into the sub-osteoclastic space — and cease bone resorption. Calcitonin also inhibits carbonic anhydrase II, reducing proton secretion required to dissolve hydroxyapatite, and suppresses differentiation of osteoclast precursors, reducing total osteoclast number with prolonged use.

A distinct analgesic mechanism operates through CTRs expressed in pain-processing central nervous system regions. Animal data indicate calcitonin's antinociceptive effect is serotonergic rather than opioidergic (naloxone does not block it) and may additionally involve inhibition of prostaglandin E2 synthesis and modulation of voltage-dependent sodium channels in sensitized neurons.

A key pharmacodynamic limitation is tachyphylaxis: osteoclasts and other CTR-expressing cells downregulate receptor surface density with continuous calcitonin exposure, diminishing antiresorptive efficacy within 24 to 48 hours of sustained use.

Calcitonin received initial FDA approval in 1975. The most influential controlled trial for its postmenopausal osteoporosis indication is the Prevent Recurrence of Osteoporotic Fractures (PROOF) study (Chesnut et al., Am J Med, 2000; PMID 10996576): a five-year, randomized, double-blind, placebo-controlled trial enrolling 1,255 postmenopausal women with established osteoporosis at 47 clinical sites. Women assigned to 200 IU intranasal salmon calcitonin daily experienced 33% fewer new vertebral fractures than the placebo group (relative risk 0.67, 95% CI 0.47 to 0.97, P = 0.03). The 100 IU and 400 IU dose arms did not achieve statistical significance, demonstrating a non-linear dose-response. Lumbar spine bone mineral density (BMD) increased approximately 1 to 1.5% from baseline. No significant reduction in non-vertebral fractures was demonstrated.

Subsequent pooled analyses present a more mixed picture. A 2025 meta-analysis in Frontiers in Pharmacology (PMC12515915; 6 RCTs, n = 8,653 patients, mean ages 65 to 80 years) found no statistically significant effect on vertebral fractures (HR 0.93, 95% CI 0.77 to 1.14) or non-vertebral fractures (HR 0.97, 95% CI 0.76 to 1.24), and only marginal BMD gains, suggesting the fracture benefit seen in PROOF may not generalize uniformly across formulations and populations.

For acute vertebral compression fracture pain, evidence is more consistently favorable. A 2020 updated systematic review and meta-analysis published in CJEM (Boucher et al., PMID 32188529; 11 studies, predominantly adults aged 60 and older) found that salmon calcitonin 100 to 200 IU IM or nasal spray daily significantly reduced acute fracture pain at one week with high certainty of evidence and a number needed to treat of approximately two.

In Paget's disease of bone, controlled trials demonstrate that calcitonin produces more than 30% reductions in serum alkaline phosphatase in approximately two-thirds of patients treated. However, roughly 26% of Paget's patients develop neutralizing anti-calcitonin antibodies with long-term use, leading to loss of biochemical and clinical response; bisphosphonates are now the preferred first-line therapy.

For hypercalcemia of malignancy, calcitonin at 4 to 8 IU/kg reduces serum calcium by 1 to 2 mg/dL within four to six hours — the fastest pharmacological onset among available agents — but tachyphylaxis limits this effect to approximately 24 to 48 hours, necessitating concurrent bisphosphonate administration for sustained calcium control.

Typical dosage: 100-200 IU (daily).

The following dosing information reflects FDA-approved labeling and published clinical trial data.

Postmenopausal osteoporosis (intranasal): 200 IU (one spray) administered into one nostril daily, alternating nostrils each day. This is the only intranasal dose with demonstrated vertebral fracture risk reduction in the PROOF trial; the 100 IU and 400 IU doses were not statistically effective in that study.

Postmenopausal osteoporosis (parenteral): 100 IU subcutaneously or intramuscularly once daily. Parenteral bioavailability (~66%) substantially exceeds that of the nasal spray (~3%).

Paget's disease of bone: 100 IU subcutaneously or intramuscularly daily initially. Once serum alkaline phosphatase normalizes, maintenance dosing of 50 IU daily or 50 to 100 IU every one to three days may be used. Monitoring for antibody-mediated resistance is warranted in patients with inadequate biochemical response.

Hypercalcemia (acute management): 4 IU/kg body weight subcutaneously or intramuscularly every 12 hours. If serum calcium does not decrease adequately within one to two days, the dose may be escalated to 8 IU/kg every 12 hours, and further to 8 IU/kg every six hours for refractory cases. A bisphosphonate is routinely co-administered given calcitonin's tachyphylaxis.

Acute vertebral compression fracture pain (off-label): Clinical trials reviewed by Boucher et al. (2020) used 100 to 200 IU IM or nasal spray daily for durations of 14 days to six months; this application is not in current FDA-approved labeling.

All calcitonin regimens require concurrent calcium supplementation (approximately 1,000 mg elemental calcium per day) and vitamin D (400 to 1,000 IU per day) to reduce hypocalcemia risk. Injection sites should be rotated; skin testing prior to parenteral administration is advisable in patients with suspected hypersensitivity to salmon or fish products.

This information is provided for educational purposes only and does not constitute medical advice. Calcitonin is a prescription medication that must be used under the supervision of a qualified healthcare provider.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Calcium and vitamin D supplementation are mandatory co-therapies explicitly required by the prescribing information. Co-administration prevents hypocalcemia that can result from acute suppression of bone resorption, and this combination is standard of care rather than merely anecdotal.

Sequential use of calcitonin followed by a bisphosphonate is the most clinically established multi-drug strategy. Because calcitonin acts rapidly but undergoes tachyphylaxis, clinical guidelines and expert opinion support using calcitonin as a short-term bridging agent in acute hypercalcemia or acute vertebral fracture pain, after which a bisphosphonate (alendronate, zoledronic acid, or risedronate) provides more durable antiresorptive therapy. Robust head-to-head RCT data for the formal concurrent combination of both drug classes are limited; this sequencing approach is based on pharmacological rationale and clinical practice experience rather than dedicated randomized trials.

Concurrent dual antiresorptive therapy (calcitonin plus a bisphosphonate simultaneously, long-term) is not a guideline-endorsed strategy. Available data are from small observational studies only, and there is a theoretical additive risk of hypocalcemia.

For acute vertebral fracture pain, clinical trials have compared calcitonin favorably to NSAIDs. Clinicians sometimes incorporate calcitonin alongside standard analgesic regimens as an opioid-sparing approach; this application is supported by the systematic review data reviewed above but formal multi-drug analgesic combination trials are lacking.

Calcitonin is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Nasal irritation (spray form), nausea

The safety profile of calcitonin is well characterized given more than four decades of post-marketing use.

Common adverse effects with parenteral administration include nausea with or without vomiting (approximately 10% of patients), facial flushing (2 to 5%), and injection site reactions including erythema, swelling, and tenderness (approximately 10%). Gastrointestinal symptoms typically diminish with continued therapy. Pruritus and tingling in the extremities are less common but reported.

The intranasal formulation produces a distinct adverse effect profile: rhinitis, epistaxis, and in some cases nasal mucosal ulceration. Prescribing information advises periodic nasal examination during treatment; therapy should be discontinued if ulcers exceeding 1.5 mm in diameter are detected.

Hypersensitivity reactions, including anaphylaxis with reported fatalities, are a recognized serious risk, particularly in patients with documented allergy to salmon or fish. A skin test may be performed before initiating parenteral calcitonin in individuals with suspected sensitivity.

Hypocalcemia can result from acute suppression of bone resorption, potentially causing tetany, seizures, or cardiac arrhythmias in predisposed patients (for example, those with vitamin D deficiency or hypoparathyroidism). Mandatory calcium and vitamin D supplementation mitigates this risk.

The most significant long-term safety concern is a signal for increased malignancy. A meta-analysis of 21 randomized controlled trials referenced in the current prescribing information identified higher malignancy rates in calcitonin-treated patients (4.1%) versus placebo (2.9%). In response, the FDA recommends the nasal spray formulation only for patients who cannot tolerate or are ineligible for first-line osteoporosis therapies. No black box warning has been issued. A subsequent 2025 meta-analysis (PMC12515915; n = 8,653) did not identify a statistically significant cancer signal, so the magnitude of this risk remains under active scrutiny.

Anti-calcitonin antibody formation affects approximately 26% of patients receiving long-term Paget's disease treatment, resulting in clinical resistance.

Clinically relevant drug interactions include agents that perturb calcium homeostasis (etelcalcetide, foscarnet, zoledronic acid) and lithium. Calcitonin is not recommended during pregnancy or lactation due to insufficient human safety data. No hepatic dose adjustment is required; caution is warranted in severe renal impairment.